Table 3 Preferences for PA information, timing and people to practice with (% patients reporting the preference)
Cancer type | Country, no. of participants, treatment stage | Study design | Persons to provide information | Time to start PA program | People to perform PA with | Time of the day | Reference | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
(A) Oncologist, (B) Family doctor, (C) Nurse, (D) Physiotherapist, & (E) Personal trainer | (A) At diagnosis, (B) During ttt, (C) Immediately after ttt, & (D) 3–6 months after ttt | (A) Alone, (B) Family/friends, & (C) Other cancer patients | (A) Morning, (B) Afternoon, & (C) Evening | |||||||||||||||
(A) | (B) | (C) | (D) | (E) | (A) | (B) | (C) | (D) | (A) | (B) | (C) | (A) | (B) | (C) | ||||
Brain | Canada, 31, during ttt | CS | + (52) | + (26) | + (7) | + (16) | + (29) | + (7) | [87] | |||||||||
US, 106, mixed | CS | + (24) | + (5) | [88] | ||||||||||||||
Breast | Canada, 12, post-ttt | QI | + | [41] | ||||||||||||||
Canada, 524, post-ttt | CS | + (14) | + (17) | + (14) | + (35) | + (21) | + (14) | + (37) | + (18) | + (50) | + (21) | + (14) | + (21) | + (17) | + (13) | [89] | ||
NZ, 20 patients | FG | + | [51] | |||||||||||||||
US, 23, during ttt | CS | + (39) | + (13) | + (30) | + (13) | + (35) | + (26) | +(39) | + (44) | + (30) | + (9) | [55] | ||||||
Colo-rectal | Australia,10, post-ttt | QI | + | + | + | + | [56] | |||||||||||
Canada, 600, mixed | CS | + (35) | + (12) | + (25) | + (18) | + (19) | + (9) | + (22) | + (28) | + (24) | + (22) | + (12) | [91] | |||||
Netherlands, 15, mixed | QI | + | + | + (53) | [92] | |||||||||||||
Endometrial | UK, 16 women, post-ttt | QI | + | [60] | ||||||||||||||
Gynecologic | Canada, 239 women | MM | + (63) | + (79) | [44] | |||||||||||||
Lung | Australia, 7, post-ttt | FG | + | + | + | [63] | ||||||||||||
US, 43, pre-ttt | CS | + (23) | + (19) | + (2) | + (12) | + (7) | + (16) | + (47) | + (21) | + (7) | + (23) | + (40) | + (7) | [65] | ||||
US, 175, post-ttt | CS | + (58) | + (8) | + (36) | + (9) | + (8) | + (13) | + (3) | [38] | |||||||||
Ovarian | Canada, 359, mixed | CS | + (18) | + (13) | + (26) | + (26) | + (49) | + (15) | + (17) | + (29) | + (31) | + (16) | [45] | |||||
Variousa | Australia, 92, during ttt | CS | + (18) | + (17) | + (9) | + (41) | + (21) | + (35) | [94] | |||||||||
Ireland, 41, mixed | FG | + | + | + | + | [77] | ||||||||||||
Italy, 392, mixed | CS | + (57) | + (7) | + (30) | + (20) | + (48) | + (31) | + (9) | + (16) | + (8) | + (27) | [46] | ||||||
Norway, 7, during ttt | QI | + | [80] | |||||||||||||||
UK, 12, mixed stages | QI | + | + | + | + | [36] | ||||||||||||
UK, 26, mixed stages | FG | + | + | + | + | + | [84] | |||||||||||
UK, 456, post-ttt | CS | + (17) | + (14) | + (11) | + (23) | + (7) | + (5) | + (25) | + (34) | + (20) | +(15) | + (15) | + (19) | + (38) | [43] | |||
US, 20, during ttt | QI | + (80) | [85] | |||||||||||||||